[ad_1]
According to Rugilė Pilvinienė, senior advisor to the Office’s Pharmacovigilance and Poisoning Information Unit, six reports of five suspected adverse reactions to the vaccine have so far been received, all of which have passed.
“Basically, all five of the five suspicious adverse reactions that we received were categorized, classified as mild,” he told BNS.
According to R. Pilvinienė, several vaccinated people reported experiencing headaches or muscle aches, and fever was recorded. Two people also experienced mild pain at the injection site, in addition to these symptoms, one person reported mild pain and pressure at the injection site, mild itching.
According to her, suspected adverse reactions were reported by both men and women aged 27 to 44 years.
“In fact, it has already been reported that (the adverse reactions – BNS) have already disappeared, all are well recovered (…) and none of those who reported indicated that they needed hospital or medical treatment,” said an IWT specialist.
Both experienced people and healthcare facilities can report suspected adverse drug reactions to the service. According to current procedure, institutions must report suspected adverse reactions to IWT within 15 days of detection.
The first batch of vaccines with 9,750 doses was distributed last weekend to five major hospitals in the country; medical vaccination was started and these doses of the vaccine were used in the middle of last week. A person needs two doses of the vaccine three weeks apart to develop immunity.
On Tuesday, doctors are scheduled to continue getting vaccinated in two subsequent batches of the vaccine. In three shipments, Lithuania has received just over 40 thousand. vaccine dose.
The BioNTech and Pfizer vaccine is the first and so far the only one authorized in the European Union.
It is not allowed to publish, quote or reproduce the information of the BNS news agency in the media and on websites without the written consent of the UAB “BNS”.
[ad_2]
